Skip to main content

Table 1 KRAS mutations

From: Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

KRASmutant
Exon Codon Hot spot site Amino acid No. of patients %
2 12    24 40.6
   c.34 G > A p.Gly12Ser 1 1.6
   c.35 G > A p.Gly12Asp 15 25.4
   c.35 G > T p.Gly12Val 7 11.8
   c.35 G > C p.Gly12Ala 1 1.6
  13    4 6.7
   c.37_39 dupl p.Gly13dupl 1 1.6
   c.37 - - -
   c.38 G > A p.Gly13Asp 3 5